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Abstract
The 2011 Varsity Medical Debate, between Oxford and Cambridge Universities, brought students and faculty
together to discuss the waiving of patents for antiretroviral therapies in the developing world. With an estimated
29.5 million infected by Human Immunodeficiency Virus (HIV) in low- and middle-income countries and only 5.3
million of those being treated, the effective and equitable distribution of anti-retroviral therapy (ART) is an issue of
great importance. The debate centred around three areas of contention. Firstly, there was disagreement about
whether patents were the real barrier to the access of anti-retroviral therapy in the developing world. Secondly,
there were differing views on the effectiveness of a patent pool. Thirdly, concerns were raised over the impact of
waiving patents on research to produce new and better anti retro-viral drugs.
Background
After the success of the 2010 Varsity Medical Debate
[1], the Third Varsity Medical Debate between Cam-
bridge and Oxford Universities took place on Friday 21
st
January 2011, hosted by the Royal College of General
Practitioners. A prestigious panel of judges, including
Dr. Iona Heath, the President of the College, oversaw
the motion “This House would waive patents for anti-
retroviral therapies in the developing world.” The
motion was proposed by Cambridge and opposed by
Oxford.
There are estimated to be 29.5 million people infected
by Human Immunodeficiency Virus (HIV) in low- and
middle-income countries with only 5.3 million of those
being treated [2,3]. The effective and equitable distribu-
tion of anti-retroviral therapy (ART) to combat
Acquired Immune Deficiency Syndrome (AIDS) is con-
sequently of great importance. Furthermore, agonies
over resource distribution have been aggravated by the
current global economic climate, which has resulted in a
reduction in aid available for the provision of anti-retro-
viral therapy. While not representing a cure, treatment
with ARTs means that AIDS becomes a chronic disease,
extending life by decades. The United Nations were
unequivocal in the urgent imperative that this problem
be tackled, stating in Millennium Development Goal 6B
that we must “achieve, by 2010, universal access to
treatment for HIV/AIDS for all those who need it” [4].
Tragically, the rate of new infections continues to vastly
outstrip the provision of treatment, and the countries
facing the heaviest burden of disease are also those with
the fewest resources available to tackle the problem.
The debate questioned whether a patent waiver would
address this shortfall of healthcare provision in develop-
ing countries.
This report will summarise the arguments of Cam-
bridge University’s team in favour of waiving patents for
anti-retroviral therapies and the differing analysis of
Oxford University’st e a ms u g g e s t i n gt h a tt h i si sn o tt h e
first necessary step.
Proposition
Cambridge University proposed that all patents outside
those held by the UNITAID patent pool be waived in
the least developed countries. Pharmaceutical companies
could avoid the waiver and gain revenue from their pro-
ducts by submitting patents to the patent pool. Patent
pools have been promoted by several global health orga-
nisations, including the World Health Organisation
(WHO) and Médicins Sans Frontières [5] as a means of
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A patent pool allows any company to make use of the
patents in the pool, for a pre-arranged royalty fee. This
facilitates rapid and efficient production of generic
drugs by many different manufacturers, whilst still
allowing the initial patent holders to achieve some
income for their intellectual property. The advantages of
this model are threefold: firstly, access to patents by
multiple manufacturers increases the opportunity for
price competition between drugs. This stands in stark
contrast to the current situation of a near-monopoly
over all but the oldest ARTs held by just a few pharma-
ceutical giants. Secondly, a pool of patents facilitates
collaborative research efforts into new developments
such as combination therapies. Thirdly, this allows the
development of local manufacture of ARTs, thereby
introducing both the economic and logistical benefits of
local drug production.
The single greatest barrier to achieving universal
access to ARTs is cost: a monthly dose of maraviroc, an
HIV entry inhibitor that came onto the market in 2007,
costs approximately $870 [6]. However, the cost of gen-
eric ARTs is much lower, due to price competition
between manufacturers, and the lack of pressure to
recoup losses made during development of the drug.
For example, a recent study found that the cost of pro-
viding a year’s worth of generic ART in Haiti was $1000
[7] -only slightly more than only a month’sd o s eo fa
single patented drug. Reduced cost is not the only bene-
fit of patent pooling. The procurement of drugs is only
the first step in achieving long-term treatment for HIV
sufferers; other obstacles to success include logistical
difficulties such as heat degradation of many of the
patented products and the complexity of multi-drug
therapies. Historically, generic products have been man-
ufactured that overcome these problems - in particular
new combination therapies that increase patient compli-
ance by simplifying complicated dose regimens and the
development of heat-stable therapies. Traditionally, ART
drugs needed refrigerated storage, often leading to need-
less wastage when this storage was either unavailable or
unreliable [8]. It is impossible for generic drug compa-
nies to apply these developments to drugs that are
under patent, and the patent holders do not always con-
s i d e ri ts u f f i c i e n t l yp r o f i t a b l et od os o .H e n c ei fa l l
ARTs are either unpatented or held within the UNI-
TAID patent pool, standardized combination therapies
could be made available to the acutely vulnerable groups
that are currently not targeted by pharmaceutical com-
panies: pregnant and breast-feeding women at risk of
vertically transferring HIV to their infants, children for
whom standard therapies are too toxic, and the millions
without access to refrigerated drug storage.
Another advantage of patents being waived specifically
in developing countries is the opportunity for growth of
local manufacture. While it is true that some developing
countries currently lack the technological capacity and
infrastructure to independently manufacture ARTs,
there have been examples of successes in this area in
the past, when developing countries have made use of
voluntary or compulsory licensing of drugs to permit
local production. In South Africa, for instance, voluntary
licensing of ARTs for production by the leading generic
drug manufacturer, Aspen, resulted in sustainable local
production of ARTs with particularly low prices for the
public sector [9]. Although many sub-saharan countries
would be unable to develop local production, these
countries would still be able to import generic drugs
legally and hence this could take place until manufactur-
ing ability could catch up. Successful development of
local manufacture in some, and eventually many coun-
tries could improve accessibility of therapies and
streamline domestic procurement systems, having a sig-
nificant impact upon public health as well as having the
potential to create jobs and improve infrastructure.
Waiving patents for ARTs in the developing world
would reduce their cost, promote development of inno-
vative solutions to the unique context of different
regions, and facilitate more efficient distribution of
treatment to those who most need it. The main argu-
ments of the proposition are summarised in table 1.
Opposition
The team from Oxford University presented the opposi-
tion case that waiving patents was not a solution to the
mutually agreed problem of ART distribution in the
developing world, and went further to argue that waiv-
ing patents could be detrimental to the efforts against
HIV/AIDS.
Intellectual property rights exist for several purposes,
not least of which is to ensure monetary reward for the
owner of the patent. Pharmaceutical companies are
often characterized as profiteering, more interested in
their own gain than in the benefit of the end-users of
their products, patients. This characterization is not
only accurate but quite appropriate; every company is
beholden to its share-holders, and moreover an unprofi-
table company will simply cease to be. In the case of the
pharmaceutical industry, where development and manu-
facturing are both necessarily highly costly and highly
specialized, reducing profitability is potentially harmful
to all. To develop pharmaceutical products is to invest
millions into an enormously high-risk venture, relying
upon the product to pass scrupulous safety and efficacy
testing, carried out at great expense to the developer -
estimates of overall cost vary from 500 million to over
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context of ARTs?
Drug development for diseases that predominantly
affect the developing world is already a precarious busi-
ness. We see in the case of orphan drugs [11], incenti-
vizing companies to invest in research and development
(R&D) for rare or unprofitable diseases is expensive and
costly in diplomatic reserve on the part of governments
or organisations involved and is rarely successful. Con-
sistently it is apparent that pharmaceutical companies
will only invest into R&D for diseases which are consid-
ered profitable. To waive patents for ARTs in the devel-
oping world would be to wave a banner saying investing
in HIV in the developing world is to pour money down
the drain- worse, to pour money into your rivals’ pock-
ets. It can be argued that the developing world repre-
sents an insignificant fraction of the market for ARTs,
and that the profit from patents in the developed world
would continue to support research and development.
T h e r ea r et w op r o b l e m sw i t ht h i sa n a l y s i s :f i r s t l y ,t h e
numbers do not hold up. Sub-Saharan Africa alone has
over 22.5 million patients infected with HIV compared
to 860,000 in the whole of Western Europe [3] - even
with poor access to ART, the developing world repre-
sents an incredibly significant fraction of the market.
Further, only approximately 5.3 million people out of a
possible 14.6 million (36%) eligible patients in low and
middle income countries received ART in 2009 [12].
This compares to approximately 50,300 out of a possible
64,600 (78%) eligible patients receiving treatment in the
UK in the same year [13]. Clearly, the developing world
currently represents the largest potential marketplace
for ARTs.
This brings us to the second problem: as we have
already seen in the guise of heat-resistance, problems
exist in many developing countries that do not in the
developed world. To chip away at profit in the devel-
oping world is to disincentivise those best placed to
tackle these problems from attempting to do so.
Finally, a patent waiver would send the message that
treatments which primarily benefit developing nations
can never be profitable - hence undermining efforts to
encourage investment in this sector. Waiving patents
in these countries could be a devastatingly short-ter-
mist approach to the problem, in the long-term harm-
ing those it is intended to help. There is direct
evidence of the harm that can be wrought by a patent
waiver - in 2007 Abbott (the world’s1 0
th biggest phar-
maceutical company) were so angered by Thailand’s
decision to ignore patents that they did not apply for
licenses to sell their latest products there, one of
which was a new heat-resistant formula, which would
have been particularly helpful for the hot South East
Asian climate.
In the long-term, then, money certainly seems to be
the primary problem. But is it the case, as it has been
contended, that the cost of ARTs is the greatest barrier
to their effective distribution? And are patents to blame
for this? There is evidence to suggest that the answer to
both of these questions is no.
The Agreement on Trade Related Aspects of Intellec-
tual Property Rights (TRIPS) agreement between World
Trade Organisation (WTO) member countries was the
first international agreement on intellectual property
law. Among other outcomes, TRIPS stipulated that
member states respect patent law. Although all provi-
sions apply equally to all members, developing countries
were given a transition period, until 2016, before
changes to their domestic laws regarding pharmaceutical
patents need to be put in place [9], and many countries
made use of the transition period. We thus have a
model within which to examine the effects of a system
whereby patents are enforced in the developed world
but not in the developing world. One study examined
the patent-status and accessibility of 15 different ARTs
in 53 African countries in 2002 and found that the
drugs were patented in very few of those countries
(median 3; mode 0)[14]. The accessibility of ARTs did
not correlate with patent coverage. This suggests that,
while the “Big Pharma” giants offer an appealing scape-
goat for a global tragedy, the situation is far more com-
plex than it first appears and indeed waiving patents
may not be as effective as proposed. The barriers to
ART in the developing world are many, and while drug
cost is certainly an enormous issue, some developing
countries have shown that gains can be made without
the drastic and potentially harmful course suggested by
the proposition.
This brings us finally to some of the alternative targets
for intervention. One of the many difficulties in success-
ful ART is the risk of resistance to first-line therapy
developing. Resistance develops most rapidly in the con-
text of unplanned interruptions of treatment, often a
consequence of poorly managed procurement strategies
in developing countries [15]. Malawi provides us with
an excellent model [16] for coping with this problem:
developing a nationwide standardized program of ther-
apy simplifies the process of matching supply to demand
and of eventual distribution. Another advantage of this
system is that it reduces the need for medically trained
staff, who face an overwhelming patient to staff ratio in
many developing countries. Lay staff can relieve this
burden and provide effective care in regions with limited
medical resources.
Improving access to ARTs in the developing world is
an indisputably important goal. However, to target
p a t e n t si st om i s sm a n yo ft h et r u eb a r r i e r st oA R T
access and, in the long-term, may be seriously
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tion of many smaller, fine-tuned changes such as those
to national HIV/AIDS strategies has been a more effec-
tive and practical alternative.
Key issues
The debate centred around three major points of dis-
agreement:
1. What is the true barrier to ART access in the
developing world?
2. Would waiving patents increase access?
3. In the long-term, is waiving patents beneficial?
1. What is the true barrier to ART access in the
developing world?
Poverty is undeniably a barrier to ART distribution in
the developing world; limited international and domestic
funds available for HIV/AIDS treatment mean that the
high prices of many drugs make them quite simply
unaffordable. Even the cost of generic drugs, however,
often exceeds the means of the millions who subsist on
less than $1 a day. The problems are thus multifactorial:
as well as financial resources, human resources are
strained in countries such as Tanzania or Malawi where
the ratio of patients:doctors exceeds 50,000:1 (compared
to 440:1 in the UK)[17]. Efficient and specialized man-
agement is needed to assess regional needs and to deli-
ver treatments appropriately and sustainably.
2. Would waiving patents increase access?
T h ee v i d e n c eo nt h i si s s u ea p p e a r st ob em i x e d .O nt h e
one hand, it is clear that the amount of money available for
ARTs in the developing world is limited by national
resources and international aid. For this reason, reducing
drug costs by waiving patents would be of obvious benefit.
This analysis is at odds with evidence available from coun-
tries that did not uphold patents prior to the TRIPS agree-
ment [9]. It seems likely, therefore, that waiving patents is
not a sufficient intervention to improve access when imple-
mented alone and can even be viewed as having uninten-
tional detrimental consequences [18]. Organisations such
as UNITAID support multilateral developments, and mea-
sures such as voluntary licensing agreements with which
pharmaceutical companies reap the benefits of waiving
patents with fewer of the harms outlined by the opposition.
It is a combination of measures, from improving infrastruc-
ture, education and prevention alongside any patent waiv-
ers via voluntary licensing agreements that will ultimately
bring most benefit.
3. In the long term, is waiving patents beneficial?
The major argument opposing the waiving of patents is
the long-term harm to investments in research and
development. The costs of developing any drug are
enormous, and the risk of the investment is very high. It
can be argued that the pharmaceutical industry is
already beginning to limit the scope of research and
development, by more often investigating permutations
of currently successful drugs rather than investigating
entirely novel classes. However, the model proposed by
Cambridge would not entirely deprive companies of the
opportunity for profit- royalties would be paid for any
patent submitted to the patent pool. This may therefore
ameliorate the harms of profit reduction. Nonetheless,
this remains a significant consideration in the approach
to HIV/AIDS in the developing world. It may be that
solutions engineered through co-operation with the
pharmaceutical industry are a good compromise. By
running an index of pharmaceutical companies and
highlighting their good and poor practices, The Access
to Medicine Foundation encourages socially responsible
behaviour from Big Pharma - for example the issuing of
five voluntary licensing agreements to generic drug
companies in sub-Saharan Africa by Merck&Co [19].
Pharmaceutical companies are also not the only route
for therapeutic innovation, and the work of groups such
as the Bill and Melinda GatesF o u n d a t i o ni ns e e k i n ga
vaccine against HIV [20] provides another avenue for
future progress. This approach, as well as other projects
such as public-private partnerships could be a very
rewarding strategy and merit more attention.
Discussion
After lengthy deliberation, the judges narrowly awarded
victory to Oxford. The judges praised the knowledge
and charisma of all the debaters and praised the Cam-
bridge team for their model. The Oxford debaters were
able to show successfully in this debate that waiving
patents with the method favoured by the proposition
might have three key unintended consequences. Firstly,
there might be a reduction in R&D in future or more
innovative ARTs. Secondly, the move might send a mes-
sage that any drugs for developing countries will never
be profitable. Thirdly, twisting the arm of pharmaceuti-
cal companies might make them resentful and less
amenable to future public-private initiatives. Further-
more, they were able to explain that there are a number
of other barriers to achieving distribution of ARTs.
These included additional to cost of drugs, distribution
logistics, complex therapeutic regimes, heat degradation
of medicines, poor political will and lack of healthcare
infrastructure and patient education.
The issues brought up at the debate are applicable to
many other infectious diseases in the developing world
and there are a number of key points to consider. The
ability to purchase ARTs, or indeed any other therapy,
in a sustainable manner does require substantial revenue
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exclusively on having the money available to pay for
drugs. In reality, obstacles to progress are often multi-
factorial. Professor Thomas Pogge has proposed a model
similar to that described by the Proposition. He suggests
the creation of a Health Impact Fund, where companies
that signed up would forgo monopoly pricing, offering
their product at cost price, in exchange for a reward
based on the global health impact of the new medicine.
He highlights the efficiency of this mechanism in maxi-
mising spending on impactful solutions, and suggests
that the wealthy will also benefit through fewer drug
resistant disease strains and potentially through lower
costs [21].
Research in areas that may not be profitable in devel-
oped countries needs to be encouraged. Encouraging
private sector involvement is one way to encourage
innovation; however, just because research is being pro-
duced by means of profit-making institutions does not
imply that this is the only (or best) way to encourage
the development of new treatments. The Opposition did
n o tp r o v i d ea n ye v i d e n c ef o rac a u s a lr e l a t i o n s h i p
between the profit motive and new drugs.
While it may be a laudable aim to encourage growth
within the economies of developing countries, Kenneth
S h a d l e ns u g g e s t st h a ti tm a yb ed i f f i c u l tf o rc o u n t r i e s
to develop their medical industries around TRIPS.
Incentives are misaligned by new regulation, such that
those firms who have capacity to produce do not want
to, since antiretrovirals carry a high cost burden and
will be sold at low prices. Generics firms with capacity
a r em o r el i k e l yt oe n t e rt h es p e c i a l i s e dg e n e r i c sm a r -
ket, where resources must be invested to produce the
drug but where the capacity for profit is high. Conver-
sely, those firms who would like to enter the antiretro-
viral generic market typically will not have the capacity
to do so. These barriers to entry are in fact part of the
rationale for TRIPS, in providing the research-based
pharmaceutical sector with protection from generic
firms [22].
The problems of infrastructure include transport and
storage. Building healthcare systems in developing coun-
tries requires sustained political will. Non-governmental
organisations such as The Bill and Melinda Gates Foun-
dation are vital for innovation, for the greatest risks
have the greatest potential for reward.
At the heart of this debate lies a tension between
intellectual property rights and human rights. There is
always a balance to strike between ensuring there are
rewards for innovation and ensuring that people suffer-
ing from diseases have access to treatments that facili-
tate better health and enjoyment of other human rights.
There is no easy answer to this question; however, the
substance of this debate provokes many questions as to
the ethical and equitable distribution of resources for
the benefit of the world’s population.
About the Debate
The Varsity Medical Debate was started in 2008 with
the aim of creating a discourse on pertinent ethical
issues among medical students. Utilising the age-old riv-
alry between the two Universities, it encourages medics
from both Oxford and Cambridge to consider and
articulate the crucial arguments surrounding questions
that will feature heavily in their future careers. Whilst
the debaters may not necessarily agree with their allo-
cated side, the debate format forces them to articulate a
certain school of thought and present the key arguments
to support this.
As well as being judges on the logic of the analysis
provided and evidence presented, participants are judged
on style and delivery. As such, although Oxford were
awarded a victory for opposing the motion, this does
not mean that they or the judges were making a truth
claim regarding the problem of access to ARTs.
This meeting report aims to chronicle the proceedings
of the debate and explain both sides of the argument to
allow for consideration of this important issue.
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